{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:25:30Z","timestamp":1788452730181,"version":"build-2803163510"},"reference-count":16,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"DOI":"10.1001\/jamaoncol.2026.3016","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:03:58Z","timestamp":1788451438000},"source":"Crossref","is-referenced-by-count":0,"title":["CAR T-Cell Therapy in Acute Lymphoblastic Leukemia\u2014Is Limited Persistence Enough?"],"prefix":"10.1001","author":[{"given":"Giovanna","family":"Lucchini","sequence":"first","affiliation":[{"name":"Paediatrics Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Ottaviano","sequence":"additional","affiliation":[{"name":"Paediatrics Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Biondi","sequence":"additional","affiliation":[{"name":"Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy"},{"name":"School of Medicine and Surgery, University of Milano-Bicocca, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"ced260005r1","article-title":"Bicistronic CD19\/CD22 CAR T-cell therapy in pediatric B-Cell acute lymphoblastic leukemia: a nonrandomized clinical trial.","author":"Wan","year":"2026","journal-title":"JAMA Oncol"},{"issue":"5","key":"ced260005r2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"ced260005r3","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"ced260005r4","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial.","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"20","key":"ced260005r5","doi-asserted-by":"publisher","first-page":"5249","DOI":"10.1182\/bloodadvances.2025015881","article-title":"Real-world data for tisagenlecleucel in patients with R\/R B-ALL: subgroup analyses from the CIBMTR registry.","volume":"9","author":"John","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"ced260005r6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia.","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"ced260005r7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41408-024-01038-2","article-title":"Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r\/r ALL through a national access scheme.","volume":"14","author":"Oporto Espuelas","year":"2024","journal-title":"Blood Cancer J"},{"issue":"4","key":"ced260005r8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1182\/blood.2024026655","article-title":"Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.","volume":"146","author":"Silbert","year":"2025","journal-title":"Blood"},{"issue":"10","key":"ced260005r9","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"issue":"10","key":"ced260005r10","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"issue":"5","key":"ced260005r11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","article-title":"CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis.","volume":"40","author":"Fischer","year":"2017","journal-title":"J Immunother"},{"issue":"4","key":"ced260005r12","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1182\/bloodadvances.2024013586","article-title":"Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.","volume":"9","author":"de Oliveira Canedo","year":"2025","journal-title":"Blood Adv"},{"issue":"10","key":"ced260005r13","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat Med"},{"issue":"27","key":"ced260005r14","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia.","volume":"39","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"key":"ced260005r15","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1182\/blood-2025-5118","article-title":"Chimeric antigen receptor (CAR) T-cell persistence at month 3 predicts clinical outcomes in adult patients with relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL) treated with obecabtagene autoleucel (obe-cel).","volume":"146","author":"Roddie","year":"2025","journal-title":"Blood"},{"issue":"10","key":"ced260005r16","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1182\/bloodadvances.2025018604","article-title":"CD19 CAR T-cell outcomes in relapsed\/refractory extramedullary B-ALL: a multisite, retrospective cohort review.","volume":"10","author":"Rankin","year":"2026","journal-title":"Blood Adv"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2853846\/jamaoncology_lucchini_2026_ed_260005_1788206493.28753.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:04:00Z","timestamp":1788451440000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2853846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":16,"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.3016","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,3]]}}}